

Proteinuria Primer


Sheldon Tobe, MD, MScCH (HPTE), FRCPC, FACP, FAHA

Hypertension and Nephrology Professor of Medicine, University of Toronto and Northern Ontario School of Medicine Post Graduate Fellowship Director, Adult Nephrology, University of Toronto



Proteinuria Predicts Renal Events


PREVEND: Albuminuria Predicts Stage 3 CKD at Year 4 (N=6894)



CKD, chronic kidney disease Verhave JC, et al. Kidney Int Suppl. 2004 Nov;(92):S18-21.




IDNT: Doubling of Scr or ESRD by Baseline Proteinuria




ESRD, end-stage renal disease; sCR, serum creatinine Atkins RC, et al. Am J Kidney Dis. 2005 Feb;45(2):281-7.

RENAAL: Baseline Proteinuria Predicts Both Renal and CV Event Rate in T2DM




CV, cardiovascular; ESRD, end-stage renal disease; T2DM, type 2 diabetes mellitus de Zeeuw D, et al. Kidney Int. 2004 Jun;65(6):2309-20.






Framingham: Progressive Increase of Renal and CV Risk For Rates of Albumin Excretion within the Normal Range in T2DM



CV End-Point
1.0
1.9
9.8



PREVEND; Albuminuria as a Predictor of CV Mortality the General Population (n=~40.000)



albumin concentration (mg/L)

CV, cardiovascular Hillege HL, et al. Circulation. 2002 Oct 1;106(14):1777-82.




Incidence and Risk of CV Events in Participants With and Without Baseline **Microalbuminuria by Randomized Group**

Total Mortality: Diabetes

No MAU

HOPE Study



CV, cardiovascular Gerstein HC, et al. JAMA. 2001 Jul 25;286(4):421-6.





Percent of CKD Patients First Reaching ESRD or Death

	CKD Stage		
(N = 27,998)	2	3	4
ESRD	1.1	1.3	19.9
Death Prior to ESRD	19.5	24.3	45.7

CKD, chronic kidney disease; ESRD, end-stage renal disease Keith DS, et al. Arch Intern Med. 2004 Mar 22;164(6):659-63.



Summary Renal and CV Outcomes with Proteinuria and Low GFR

Low eGFR is associated with a greater risk of renal progression and greater CV risk Albuminuria is associated with a greater risk of renal progression and greater CV risk

CV, cardiovascular; eGFR, estimated glomerular filtration rate




Stage of Kidney Disease	Normal		Microalbuminuria (30-300 mg/day)		Overt Nephropathy (≥ 1g/day)	
Type of Event Study	Mortality	ESRD	Mortality	ESRD	Mortality	ESRD
ONTARGET (ramipril arm N=8576, 4.7 year follow-up)	2.5	0.13				
HOPE diabetes cohort (n=1808, 4.5 year follow-up)	2.4	0.1				
ADVANCE Type 2 diabetes (n=7877, 4.3 year follow-up)	1.4	0.04	2.7	0.18		
LIFE Study (losartan arm n=4126, 4.8 year follow-up)	1.14	_	2.6	0.5		
UKPDS (64) Type 2 Diabetes* (overall n=5097, 10 year follow-up)	1.4	0.1	3.0	0.3	4.6	2.3
AASK Trial (amlodipine and metoprolol arm, n=658, 4.1 year follow-up)	All cause m progressio		mes more likely	to occur than	5.2	5.1
RENAAL** Type 2 diabetes (n=1513, 3.4 years follow-up)		All cause mortality 5-15 times more likely to occur than progression to ESRD			6.6	9.1
IDNT Type 2 diabetes (n=1715, 2.5 years)		nortality event 1 ession to ESRD	5 + times more l	ikely to occur	6.5	7.1

ESRD, end-stage renal disease Tobe SW, Dai MO. Curr Hypertens Rep. 2009 Oct;11(5):345-53.



ONTARGET: CV and Renal Outcomes GFR x Albuminuria



- 1. Dialysis << death for all but macroalbuminuria
- 2. Both low GFR and albuminuria significantly increase the risk of death

CV, cardiovascular; GFR, glomerular filtration rate Tobe SW, et al. Circulation. 2011 Mar 15;123(10):1098-107.






Proteinuria Reduction

Is proteinuria reduction associated with improved outcomes?

Does targeted proteinuria reduction lead to improved outcomes?



Relationship Between Achieved Urine Albumin Concentration and the Combined Renal Outcome of Doubling of Serum Creatinine and ESRD




ESRD, end-stage renal disease Tobe SW, Dai MO. Curr Hypertens Rep. 2009 Oct;11(5):345-53.






IDNT: Magnitude Of Change in Proteinuria in the First 12 Months Predicts Eventual Renal Endpoints



Atkins RC, et al. Am J Kidney Dis. 2005 Feb;45(2):281-7.

AASK: Risk of ESRD By Change In Urine Protein Across All Groups (Metoprolol, Ramipril, Amlodipine)




Change in UP: Cr, %


ESRD, end-stage renal disease Lea J, et al. Arch Intern Med. 2005 Apr 25;165(8):947-53.



Albuminuria Reduction at 6 Months Predicts CV Endpoints and CHF

RENAAL Study






CHF, chronic heart failure; CV, cardiovascular de Zeeuw D, et al. Circulation. 2004 Aug 24;110(8):921-7.

Albuminuria reduction (%)



The ONTARGET Trial



*Planned. Actual=25,620; †Planned. Actual=5926. ONTARGET/TRANSCEND Investigators. Am Heart J. 2004 Jul;148(1):52-61.

Full doses at 2 years:ramipril81.7% mono
75.3% combotelmisartan88.6% mono
84.3% combo




ONTARGET: Components of the Composite Renal Outcome

	Ramipril (n = 8,576)	Telmisartan (n = 8,542)	Combined (n = 8,502)	P (combined vs ramipril)
All deaths	1014	993	1065	0.14
Doubling s.create.	140	155	166	0.11
ESRD	33	31	34	0.85
Acute dialysis*	13	20	28	0.02

*Duration < 2 months ESRD, end-stage renal disease Mann JF, et al. Lancet. 2008 Aug 16;372(9638):547-53.



Change in ACR by Baseline Proteinuria and Dual vs Mono Therapy



ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate Tobe SW, et al. Circulation. 2011 Mar 15;123(10):1098-107.




The Role of Dual RAAS Blockade with an ACEi and ARB vs Monotherapy

Purpose of sub-analysis:

Even though ONTARGET did not show an improvement in CV and renal outcomes overall, maybe dual RAASi would benefit a subgroup of patients with low GFR and macroalbuminuria

ACEi, angiotensin-converting-enzyme inhibitors; ARB, angiotensin-receptor blockers; CV, cardiovascular eGFR, estimated glomerular filtration rate; RAASi, renin-angiotensin aldosterone system inhibitor





Tobe SW, et al. Circulation. 2011 Mar 15;123(10):1098-107.






Low GFR: 5623 GFR 60 +: 16,799 Normoalbuminuria: 18,326 Microalbuminuria: 3,809 Macroalbuminuria: 1,287 Monotherapy: 15,646 Dual Therapy: 7776

GFR	Low (Low GFR (eGFR < 60)			I GFR (eGF	R 60+)
U Alb	Norm	MAU	Macro	Norm	MAU	Macro
Ν	3837	1178	608	14489	2631	679
Mono	2568	767	417	9656	1775	463
Dual	1269	411	191	4833	856	216

eGFR, estimated glomerular filtration rate Tobe SW, et al. Circulation. 2011 Mar 15;123(10):1098-107.



ONTARGET: CV and Renal Outcomes GFR x Albuminuria



CV, cardiovascular; GFR, glomerular filtration rate Tobe SW, et al. Circulation. 2011 Mar 15;123(10):1098-107.





Summary (cont.)

- Proteinuria is both a marker and a mediator of renal damage and is associated with greater CV risk.
- In normal or microalbuminuria range of proteinuria, the rate of hard renal events (dialysis and doubling of creatinine) is much lower than the mortality rate.
- At higher levels of proteinuria (overt nephropathy), the renal event rate is still lower than the mortality rate
- Patients with overt nephropathy who achieve lower proteinuria with therapy have improved hard renal outcomes
- This has not yet been demonstrated in the microalbuminuria range.



Summary

Dual RAAS blockade or supramaximal dosing of ACEi or **ARB** reduce proteinuria more than the maximum recommended doses of monotherapy

However, evidence that dual blockade provides additional benefits for hard renal and cardiovascular outcomes is still lacking

ACEi, angiotensin-converting-enzyme inhibitors; ARB, angiotensin-receptor blockers; AKI, acute kidney injury; RAAS, reninangiotensin aldosterone system

Dual therapy increases the risk for complications such as AKI and hyperkalemia





Conclusions: Therapy for patients with nephropathy



All patients should receive treatment with the maximal recommended dose of an ACEi or ARB



Lower blood pressure to target (<130/80 for DM, < 120 for CKD)



Global risk reduction



There is currently NO evidence to support Dual therapy with an ACEi and ARB


ACEi, angiotensin-converting-enzyme inhibitors; ARB, angiotensin-receptor blockers, CKD, chronic kidney disease





Levelling-off of ESRD from Diabetes in the US: Impact of the Clinical Practice Guideline for Diabetes Over Time

Incident counts & adjusted rates of ESRD, by primary diagnosis, data from the USRDS



ESRD, end-stage renal disease

Mogensen Demonstrates the Impact of Albuminuria as a Predictor of Risk for **Progressive Renal Disease and Mortality in T2D**

- Observational study based on 1082 clinic patients with T2D in 1973
- 76 patients had MAU
- After 10 years, 5.4% of those without MAU had progressed to macroalbuminuria while 22% with MAU had progressed
- Over 50% of those without MAU at baseline were alive after 10 years, compared to only 22% of those with MAU at baseline alive at 10 years
- Of interest, the mean BP was 160/90 or greater at baseline




Pima Indian (T2D) Study: Renal Progression at Different Stages of Diabetic Nephropathy

Rate of loss of eGFR over 4 years

•Microalbuminuria: ~1 ml/min/year

•Macroalbuminuria: ~1 ml/min/month



eGFR, estimated glomerular filtration rate; T2D, type 2 diabetes Nelson RG, et al. N Engl J Med. 1996 Nov 28;335(22):1636-42.


Lifescience Technologies

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors

- Oral medication
- Mechanism of Action: eliminate glucose into the urine by reducing glucose reabsorption in the proximal tubule, leading to urinary glucose and salt excretion by osmotic diuresis
- Side effects: may include genital yeast infections, UTI, increased urination and low blood pressure
- Associated with weight loss (2-3kg) and a low risk of hypoglycemia

Generic Name	Brand Na
Canagliflozin (100mg, 300mg)	Invokana
Dapagliflozin (5mg, 10mg)	Forxiga
Empagliflozin (10mg, 25 mg)	Jardiance







In 2015, the SGLT2i Class is Found to be Renal and CV Protective in T2DM in a CVOT

- Tested in a CV outcome trial the SGLT2i empagliflozin is found to be cardiac protective mostly from reduction in CHF
- Also found to be renal protective
- This benefit was additional to that of blood pressure control and RAASi blockade

The NEW
Empagliflozio and Mor
Bernard Zinman, M.D David Fitchett, M.I Michaela Matthe Odd Erik Johansen, M.I and Silvio E. Inzucchi,

BACKGROUND

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

CHF, chronic heart failure; CV, cardiovascular; CVOT, cardiovascular outcome; RAASi, renin-angiotensin aldosterone system inhibitor; SGLT2i, Sodium-glucose co-transporter 2 inhibitor Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. Wanner C, et al. N Engl J Med. 2016 Jul 28;375(4):323-34.

ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

n, Cardiovascular Outcomes, tality in Type 2 Diabetes

., Christoph Wanner, M.D., John M. Lachin, Sc.D., .D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., eus, Dipl. Biomath., Theresa Devins, Dr.P.H., D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., M.D., for the EMPA-REG OUTCOME Investigators

ABSTRACT



Secondary Renal Outcomes from CVOTs in T2D with GLP-1, SGLT2i

Note that much of the benefit in these early studies came from preventing new onset albuminuria

	CVOT Trials in Type 2 Diabetes with GLP-1 or SGLT2i Treatment: Renal Outcomes						
	LEADER	SUSTAIN-6	EXSCEL	EMPA-REG	CANVAS Program	DECLARE	
Тх	Lira vs P	Sema v P	Exena v P	Empa v P	Cana v P	Dapa vs P	
F/up yrs	3.8	2.1	3.2	3.1	5.7	4.2	
eGFR	30+ 30+		30+ 30+	30+	60+	60+	
Secondary Outcome	New Alb , 2xCreat, RRT, renal death	New Alb , 2xCreat, RRT, renal death	New Alb , 40% ↓ eGFR, RRT, renal death	New Alb , 2xCreat, RRT, renal death	2xCreat, RRT, renal death	40%	
HR (± 95% CI)	0.78 (.6792)	0.52 (.3380)	0.85 (.7398)	0.61 (.5370)	0.53 (.3384)	0.76 (0.67-0.87)	

Compare the hazard ratios for SGLT2i to the improvement of 16-28% from RAAS blockade. This is over and above RAAS blockade!

CVOT, cardiovascular outcome; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1; HR, hazard ratio; RAAS, renin-angiotensin aldosterone system; SGLT2i, Sodium-glucose co-transporter 2 inhibitor; T2D, type 2 diabetes Hu Y. Chronic Dis Transl Med. 2019 Mar 15;5(1):25-36.



Heat Map Classification of Renal Disease with Prevalence as a Percentage of **Total**

	Мо	ost people are		Albuminuria categories			
		normal		A1 Normal to mildly increased	A2 Moderately increased	A3 Severely increased	
				<30 mg/g <3 mg/mmol	30-300 mg/g 3-30 mg/mmol	>300 mg/g >30 mg/mmol	
s 1 ²)	G1	Normal to high	>90	54.7	4.3	0.4	
Jories 73 m²)	G2	Mildly decreased	60–89	30.4	2.6	0.3	
GFR categories (mL/min/1.73 m ²)	G3a	Mildly to moderately increased	45–59	3.9	0.9	0.2	
GFR (mL/r	G3b	Moderately to severely decreased	30–44	1.0		0.2	
	G4	Severely decreased	15–29	0.1	0.1	0.22	
	G5	Kidney failure	<15	<0.001	0.001	0.01	

GFR, glomerular filtration rate; USRDS Annual Report Chapter 1 2016 (based on NHANES 2011-2014).



CREDENCE Study

- Patients:
 - T2D, age 30+, A1c 6.5%-12.0%
 - eGFR 30 90 mL/min
 - ACR 30 to 500 mg/mmol
 - On maximum tolerated dose of ACEi or ARB
- **Purpose**: Reduce progression of renal disease and CV outcomes
- Primary Composite outcome: ESRD, doubling of serum creatinine, renal or CV death
- Secondary outcomes: CV death or hospitalization for heart failure, 3-point MACE: CV death, MI, or stroke)

Participants continued treatment if eGFR was <30 mL/min/1.73 m2 until chronic dialysis was initiated or kidney transplant occurred


ACEi, angiotensin-converting-enzyme inhibitors; ACR, albumin-creatinine ratio; ARB, angiotensin-receptor blockers; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; MACE, major adverse cardiovascular event; MI, myocardial infarction Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306.







Primary Outcome: ESRD, Doubling of Serum Creatinine, or Renal or CV Death




CV, cardiovascular; ESRD, end-stage renal disease; Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306.



 Placebo Canagliflozin 				
36	42			
621 646	170 196			



Acute and Long-term Effects on eGFR



eGFR, estimated glomerular filtration rate Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306.

60% reduction in the rate of eGFR decline with canagliflozin

	_36	_42	
006	583	210	
116	652	241	On treatment



Summary

Primary	Hazard ratio (95% CI)	<i>P</i> value	
1. ESRD, doubling of serum creatinine, or renal or CV death	0.70 (0.59–0.82)	0.00001	
Secondary			 ✓
2. CV death or hospitalization for heart failure	0.69 (0.57–0.83)	<0.001	
3. CV death, MI, or stroke	0.80 (0.67–0.95)	0.01	~
4. Hospitalization for heart failure	0.61 (0.47–0.80)	<0.001	✓
5. ESKD, doubling of serum creatinine, or renal death	0.66 (0.53–0.81)	<0.001	 Image: A start of the start of
6. CV death	0.78 (0.61–1.00)	0.0502	
7. All-cause mortality	0.83 (0.68–1.02)	_	Not significant
 CV death, MI, stroke, hospitalization for heart failure, or hospitalization for unstable angina 	0.74 (0.63–0.86)		Not formally tested

CV, cardiovascular; ESRD, end-stage renal disease; MI, myocardial infarction Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306.



Summary

Primary			Ha
1. ESRD, doubling of serum creatinine, or re	ena	or CV death	07
Secondary	•	After so many year	
2. CV death or hospitalization for heart failu		patients with diab nephropathy, this	
3. CV death, MI, or stroke		improvement in o	
4. Hospitalization for heart failure	•	Note that this imp	orove
5. ESKD, doubling of serum creatinine, or re		the effect of RAA	
6. CV death			0.7
7. All-cause mortality			0.8
 CV death, MI, stroke, hospitalization for h hospitalization for unstable angina 	ear	t failure, or	0.7

Perkovic V, NEJM 2019 380: 2295-2306 CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation).

CV, cardiovascular; ESRD, end-stage renal disease; MI, myocardial infarction Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306.

azard ratio (95% CI)	<i>P</i> value	
0 (0 59–0 82)	0.00001	
of negative res and advance dy showed a c me. ement is over		
ockade and B		~
8 (0.61–1.00)	0.0502	✓
3 (0.68–1.02)	Not significant	
4 (0.63–0.86)		Not formally tested






Dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) Rationale and trial protocol

			Interventions	Follow-up	Primary outcome
	ļ.	Multicentre ~400 Target n = 4300 Patients with and without type 2 diabetes			Composite renal endpoint ≥ 50% decline in eGFR
√		≥ 18 years 25-75 mo/min/1.73 m² uACR ≥ 200 mg/g	Dapagliflozin 10 mg	~45 months	End-stage Kidney disease
×		Polycystic kidney disease Lupus nephritis ANCA vsuculitis Type 1 diabetes	Placebo	Event-driven (681 events)	Renal or cardiovascular death



DAPA CKD Primary Composite Outcome: Sustained ≥50% eGFR Decline, ESRD, Renal or **CV Death**



CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; RRR, relative risk reduction Heerspink HJL, et al. Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282.





DAPA CKD Primary Composite Outcome: Prespecified Subgroup Analyses Diabetes and No Diabetes

		Number o	f Events			
	HR (95% CI)	DAPA 10 mg (N=2152)	Placebo (N=2152)	HR	95% CI	p-value Interaction
Composite of ≥50% eGFR	Decline, ESKD, or Renal or CV Death					
All Patients		197	312	0.61	(0.51, 0.72)	_
T2D at Baseline						0.24
Yes		152	229	0.64	(0.52, 0.79)	
No	_	45	83	0.50	(0.35, 0.72)	-
UACR (mg/g) at Baseline						0.52
≤1000		44	84	0.54	(0.37, 0.77)	
>1000		153	228	0.62	(0.50, 0.76)	
eGFR (mL/min/1.73m ²) at I	Baseline					0.22
<45		152	217	0.63	(0.51, 0.78)	
≥45		45	95	0.49	(0.34, 0.69)	
	0.13 0.50 1.0	0 1.25				
	DAPA 10 mg Better	Placebo Better				

CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; T2D, type 2 diabetes; UACR, urine albumin-creatinine ratio

Heerspink HJL, et al. Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282.




Diabetes Canada: 2020 Recommendation on the Role of SGLT2i for **Prevention of Progression of Nephropathy**


In adults with type 2 diabetes and CKD and an estimated eGFR >30 mL/min/1.73m², an SGLT2i should be used to reduce the risk of progression of nephropathy.

	Patie	ents	Events	Events per 1000 Patients-years		Weight (%)	
	Treatment (n/N)	Placebo (n/N)		Treatment	Placebo		
Patients with atheroscle	rotic cardiovascu	ılar disease					
EMPA-REG OUTCOME	4645/6968	2323/6968	152	6.3.	11.5	31.0	
CANVAS program	3756/6656	2900/6656	179	6.4	10.5	35.6	
DECLARE-TMI 58	3474/6974	3500/6974	183	4.7	8.6	33.4	
Fixed effects model for	atherosclerotic ca	ardiovascular dis	ease (p<0	.0001)			
Patients with multiple ri	sk factors						
CANVAS Program	2039/3486	1447/3486	70	4.1	6.6	29.5	
DECLARE-TMI 58	5108/10186	5078/10186	182	3.0	5.9	70.5	
Fixed effects model for	Fixed effects model for multiple risk factors (p<0.0001)						

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; SGLT2i, Sodium-glucose co-transporter 2 inhibitor Diabetes Canada Clinical Practice Guidelines Expert Committee. Can J Diabetes. 2020 Oct;44(7):575-591. Zelniker TA, et al. Lancet. 2019 Jan 5;393(10166):31-39.



Secondary Composite Outcome: Sustained ≥50% eGFR Decline, ESKD, or Renal Deatha



^a ESKD defined as the need for maintenance dialysis (peritoneal or hemodialysis) for at least 28 days and renal transplantation or sustained eGFR <15mL/min/1.73m2 for at least 28 days. Renal death was defined as death due to ESKD when dialysis treatment was deliberately withheld for any reason.

DAPA, dapagliflozin; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HR, hazard ratio; RRR, relative risk reduction.

Heerspink HJL. Presented at: ESC Congress – The Digital Experience; August 29 - September 1, 2020. Heerspink HJL, et al. Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282



SGLT2i and CKD with Proteinuria


- There is now evidence to start these agents even with an eGFR down to 30 ml/min
- No Canadian CPG yet
- Other studies pending
- Wait for data on patients without albuminuria



DAPA-CKD: IgA Nephropathy Subgroup

Sub-analysis of 270 patients in DAPA-CKD with IgA nephropathy

• Similar number of patients to **TESTING and STOP-IgA**, trials with immunosuppression¹



Wheeler DC, et al. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234. Wheeler DC. FR-OR58. Oral presentation given at Kidney Week Reimagined 2020.



Conclusions

- In this pre-specified analysis, the renal, CV and mortality beneficial effects of dapagliflozin were generally seen regardless of the underlying cause of CKD, and regardless of the presence of T2DM
- Dapagliflozin was well tolerated; the safety profile was consistent across underlying causes of kidney disease

Caveats/Limitations:

- Though the subgroup analyses, was prespecified, generally speaking results should be interpreted. in this context.
- Etiology of kidney disease was determined without biopsy in the vast majority of cases (biopsy only done in 20% of patients).

CKD, chronic kidney disease; CV, cardiovascular; T2DM, type 2 diabetes mellitus Wheeler DC. FR-OR58. Oral presentation given at Kidney Week Reimagined 2020.



EMPEROR-Reduced Trial Specified Only Three Endpoints to be Tested in Hierarchical Manner



Primary Endpoint Composite of cardiovascular death or heart failure hospitalization



First Secondary Endpoint Total (first and recurrent heart failure hospitalizations)

Second Secondary Endpoint Slope of decline in glomerular filtration rate over time

Other prespecified endpoints: Composite renal endpoint, KCCQ clinical summary score, total number of hospitalizations for any reason, all-cause mortality, new onset diabetes

 Enriched for more severe LV dysfunction and marked increases in natriuretic peptides

- albuminuria

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LV, left ventricle Zannad F. FR-OR52: Oral presentation given at Kidney Week Reimagined 2020.

 >50% of patients had prevalent CKD, eGFR down to 20 ml/mg/1.73 m²

no inclusion criteria based on

• Design: After screening (4-28 days), patients randomized 1:1 to empagliflozin (10 mg daily) or placebo + their usual therapy for HF



EMPEROR-Reduced Results: Effect on all three Endpoints Specified for Hierarchical Testing was Significant

Primary endpoint: Adjudicated CV death or heart failure hospitalization	Confirmatory*	(95%
Key secondary endpoint: Adjudicated first and recurrent heart failure hospitalizations	Confirmatory [†]	(95%
Key secondary endpoint: eGFR slope	Confirmatory [‡]	1.73

*Cox regression with a=0.0496, †Joint frailty model of adjudicated HHF and CV death with a=0.0496, ‡Random intercept random slope model with a=0.001. All models include covariates age, baseline eGFR, region, baseline diabetes status, sex and LVEF; Data on file. CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure, LVEF, left ventricular

CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure, LVEF, left ventricular ejection fraction.

Zannad F. FR-OR52. Oral presentation given at Kidney Week Reimagined 2020.

HR 0.75 % CI:0.65,0.86) p<0.001

HR 0.70 5% CI:0.58,0.85) p<0.001





Slope difference ml/min/1.73 m² per year, (95% CI:1.1,2.4) p<0.001



EMPEROR-Reduced: Results

Primary endpoint: Time to first event of adjudicated hHF or CV death





Empagliflozin 1863

1826

1768

1532

1283

CV, cardiovascular; hHF, hospitalization for heart failure; CI, confidence interval. Packer M, et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190..

Key secondary endpoint: Time to adjudicated first and recurrent hHF



1008

Institute of Kidney Lifescience Technologies


272

118

495

EMPEROR-Reduced: Subgroup Analysis by CKD Status Consistent effects on the primary composite outcome


Time to first event of adjudicated HHF or CV death



	Empagliflozin	Placebo		
	n with event/N analyzed		HR (95% CI)	
Overall	361/1863	462/1867	0.75 (0.65, 0.86)	
Baseline CKD status				
With CKD	219/981	273/997	0.78 (0.65, 0.93)	
Without CKD	142/879	187/867	0.72 (0.58, 0.90)	

0.25

CI, confidence interval; CKD, chronic kidney disease; CV, cardiovascular; HR, hazard ratio; hHF, hospitalization for heart failure Zannad F. FR-OR52. Oral presentation given at Kidney Week Reimagined 2020.






Clinical Context

Empagliflozin treatment reverted the excessive risk of patients with CKD to the level of risk of the placebo group without CKD

FIDELIO-DKD Study Design



*Known significant non-diabetic kidney disease, including clinically relevant renal artery stenosis; [#]Mean sitting SBP ≥170 mm Hg or mean sitting DBP ≥110 mm Hg at the run-in visit or mean sitting SBP ≥160 mm Hg or mean sitting DBP ≥100 mm Hg at the screening visit

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus

Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713.

Key inclusion criteria

Aged ≥18 years with CKD and T2D
Pretreated with optimized therapy with either an ACEi or ARB for ≥4 weeks
Serum potassium ≤4.8 mmol/l

• Diabetic retinopathy for patients with moderately elevated albuminuria

Key exclusion criteria



HFrEF with NYHA class II–IV


• Other kidney disease*

• HbA1c >12%


• Uncontrolled arterial hypertension[#]



FIDELIO-DKD Study Design




Hierarchical endpoints



CV, cardiovascular; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; MI, myocardial infarction; R, randomization; UACR, urinary albumin creatinine ratio


Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713.





FIDELIO-DKD Study Results

Primary endpoint: Kidney failure, sustained $\geq 40\%$ decreased in eGFR from baseline, or renal death. Reduced by 18%.




ARR, absolute risk reduction; CI, confidence interval; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NNT, number needed to treat Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713.





On Top of Max Tolerated RASi Therapy, Finerenone Significantly Reduced the Risk of the Key Secondary CV Outcome by 14%

Time to CV death, non-fatal MI, non-fatal stroke or HHF




*Number of patients with an event over a median of 2.6 years of follow-up CI, confidence interval; CV, cardiovascular; HHF, hospitalization for heart failure; HR, hazard ratio; MI, myocardial infarction; RASi, renin–angiotensin system inhibition Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713.



Overall Summary

In a patient population with advanced CKD in T2D, well-controlled blood pressure and HbA1c, and treated with a maximally tolerated dose of an ACEi or ARB, finerenone significantly reduced:



Finerenone was effective for both kidney and CV protection in patients with CKD and T2D

ACEi, angiotensin converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CV, cardiovascular; HbA1c, glycated haemoglobin; SAE, serious adverse event; T2D, type 2 diabetes Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713.



The risk of CV morbidity and mortality by 14%



FIDELIO-DKD Study Results

Secondary Endpoints:

- **CV** (death from CV causes, nonfatal MI, nonfatal stroke, or HHF):
 - 14% relative risk reduction (13.0% with finerenone vs. 14.8% with placebo; HR, 0.86; 95% CI, 0.75 to 0.99; p=0.0339)
- All cause mortality: No significant reduction
- Because of hierarchical analysis, no other endpoints formally tested


Adverse events: Similar in the two groups

Hyperkalemia-related permanent drug discontinuation was higher with finerenone than with placebo (2.3% vs 0.9%)

ARR, absolute risk reduction; CI, confidence interval; CV, cardiovascular; DKD, diabetic kidney disease; HHF, hospitalization for heart failure; HR, hazard ratio; MI, myocardial infarction; NNT, number needed to treat. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713.









While hyperkalemia risk wasn't striking in the trial, it may be more problematic if applied in usual clinical practice

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; SGLT2i, sodium-glucose cotransporter-2 inhibitor



Implications for Canadian Clinical Practice

Finerenone is another novel therapy that meaningfully impacts CKD progression and cardiovascular risk in patients with diabetic kidney disease

It remains unknown the degree to which finerenone may be additive to a strategy of ACEI/ARB + SGLT2i

CKD, chronic kidney disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; SGLT2i, sodium-glucose cotransporter-2 inhibitor.

